CenterBook Partners LP Increases Stake in CeriBell, Inc. $CBLL

CenterBook Partners LP increased its holdings in CeriBell, Inc. (NASDAQ:CBLL) by 448.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 476,554 shares of the company’s stock after purchasing an additional 389,584 shares during the quarter. CenterBook Partners LP owned 1.28% of CeriBell worth $5,476,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its holdings in shares of CeriBell by 6,424.8% in the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after buying an additional 374,179 shares during the period. Peregrine Capital Management LLC bought a new position in CeriBell during the 2nd quarter worth approximately $6,399,000. TimesSquare Capital Management LLC increased its stake in CeriBell by 48.5% in the 2nd quarter. TimesSquare Capital Management LLC now owns 796,945 shares of the company’s stock worth $14,927,000 after purchasing an additional 260,116 shares during the period. Geode Capital Management LLC lifted its position in CeriBell by 55.4% in the second quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock valued at $8,391,000 after purchasing an additional 159,698 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of CeriBell by 11.1% during the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock valued at $16,935,000 after purchasing an additional 147,013 shares during the period.

Analysts Set New Price Targets

CBLL has been the subject of several recent analyst reports. Canaccord Genuity Group upped their price objective on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Raymond James Financial started coverage on shares of CeriBell in a research note on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 target price on the stock. TD Cowen reiterated a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. BTIG Research restated a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a report on Wednesday, January 28th. Finally, JPMorgan Chase & Co. reduced their target price on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $24.67.

CeriBell Price Performance

Shares of CBLL opened at $19.69 on Wednesday. CeriBell, Inc. has a fifty-two week low of $10.01 and a fifty-two week high of $26.04. The firm’s 50-day simple moving average is $21.36 and its two-hundred day simple moving average is $15.95. The stock has a market cap of $730.42 million, a PE ratio of -13.04 and a beta of 1.03. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.25 and a current ratio of 12.65.

Insider Activity at CeriBell

In other CeriBell news, CEO Xingjuan Chao sold 79,000 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $21.27, for a total value of $1,680,330.00. Following the sale, the chief executive officer directly owned 741,248 shares of the company’s stock, valued at approximately $15,766,344.96. The trade was a 9.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CTO Raymond Woo sold 11,112 shares of the firm’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $21.18, for a total value of $235,352.16. Following the transaction, the chief technology officer owned 167,317 shares of the company’s stock, valued at $3,543,774.06. The trade was a 6.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 369,656 shares of company stock worth $7,281,615 over the last quarter. 20.10% of the stock is currently owned by company insiders.

CeriBell Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.